Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174216 | 1.00 | MAPT (0.61) | MAPTRAB9AKDM4ENPC1GAA | |
| SCHEMBL25532119 | 0.88 | MAPT (0.48) | MAPTRAB9AKDM4ENPC1GAA | |
| SCHEMBL11732416 | 0.87 | MAPT (0.63) | MAPTRAB9AKDM4ENPC1GAA | |
| SCHEMBL10046419 | 0.85 | RAB9A (0.70) | MAPTRAB9AKDM4ENPC1GAA | |
| SCHEMBL208476 | 0.84 | GRM5 (0.51) | MAPTRAB9AKDM4ENPC1GRM5 | |
| SCHEMBL4687835 | 0.82 | NPSR1 (0.65) | MAPTRAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL29538166 | 0.82 | NPSR1 (0.65) | MAPTRAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL25531816 | 0.81 | POLB (0.49) | MAPTRAB9AKDM4ENPC1TDP1 | |
| Hydrochloric Acid SCHEMBL30054295 | 0.81 | NPSR1 (0.64) | MAPTRAB9ANPC1TDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL616304 | 0.81 | NPSR1 (0.64) | MAPTRAB9ANPC1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | MAPT 1805/4885RAB9A 2620/4885KDM4E 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.